Tang Jie, Li Xiu-Wen, Wu Yong, Su Zhen, He Yan, Sun Xue-Wen, Cao Xiao-Long, Li Yi-Hua, Wang Bi-Cheng, Zou Guo-Rong
Department of Oncology, Panyu Central Hospital, Cancer Institute of Panyu, Guangzhou, Guangdong 511400, P.R. China.
Department of Cardiology, Panyu Central Hospital, Guangzhou, Guangdong 511400, P.R. China.
Mol Clin Oncol. 2023 Jun 13;19(1):57. doi: 10.3892/mco.2023.2653. eCollection 2023 Jul.
Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.
放射性鼻咽坏死(RRNN)是鼻咽癌(NPC)患者中一种罕见且常致命的并发症。目前,对于RRNN尚无推荐的标准治疗方法。传统保守治疗的效果欠佳,且经验不足的医生无法对RRNN进行手术治疗。在本研究中,评估了恩度在两名RRNN患者中的应用。两名RRNN患者在番禺中心医院(中国广州)肿瘤科接受治疗。分别对一名男性患者和一名女性患者静脉注射恩度(第1天至第7天每天15 mg,每三周一次),男性患者注射四个周期,女性患者注射七个周期。使用磁共振成像(MRI)和鼻咽镜评估恩度的疗效。两名患者经恩度治疗后RRNN症状均得到缓解。MRI和鼻咽镜分析显示,鼻咽部坏死明显减轻,鼻咽溃疡愈合。恩度有可能成为治疗RRNN患者的一种新型有效疗法。然而,需要进行临床试验来证实本研究的结果。